Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies

Radiother Oncol. 2009 Sep;92(3):472-6. doi: 10.1016/j.radonc.2009.06.006. Epub 2009 Jul 1.

Abstract

Objective: Oral mucositis is a severe, dose-limiting side effect of radio(chemo)therapy for head and neck tumors. The epithelial radiation response (ulceration) is accompanied by inflammatory changes. Their interaction with the epithelial processes remains unclear. The present study was initiated to determine the effect of inhibition of TNF-alpha or COX-2 on the epithelial radiation response in the mouse tongue model.

Methods: Daily fractionated irradiation was given with 5 x 3 Gy/week over one (days 0-4) or two weeks (days 0-4, 7-11). Each protocol was terminated by graded test doses (5 dose groups, 10 animals each) to a defined area of the lower tongue surface to generate full dose-effect curves for mucosal ulceration. A TNF-alpha inhibiting antibody (Infliximab) or a COX-2 inhibitor (Celecoxib) was administered.

Results: No effect of Infliximab or Celecoxib was found in any of the protocols. Isoeffective doses for ulcer induction were unchanged. Also, the time course of the response was largely unaffected.

Conclusions: Inhibition of TNF-alpha or COX-2, two dominating inflammatory pathways, did not result in modulation of the response of oral epithelium during fractionated irradiation. This suggests that the inflammatory changes mediated through TNF-alpha or COX-2 are not relevant for the epithelial radiation response of oral mucosa.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Disease Models, Animal
  • Dose Fractionation, Radiation
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Female
  • Inflammation / etiology
  • Inflammation / prevention & control
  • Infliximab
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mouth Mucosa / pathology
  • Mouth Mucosa / radiation effects
  • Probability
  • Pyrazoles / pharmacology*
  • Radiation Injuries, Experimental / drug therapy
  • Radiation Injuries, Experimental / pathology
  • Random Allocation
  • Reference Values
  • Stomatitis / drug therapy*
  • Stomatitis / etiology
  • Sulfonamides / pharmacology*
  • Tongue / drug effects
  • Tongue / radiation effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Celecoxib